Literature DB >> 11337026

The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety.

S V Argyropoulos1, J J Sandford, D J Nutt.   

Abstract

Benzodiazepines have been the mainstay of pharmacological treatment of anxiety over the last 4 decades. The problems associated with their use prompted the research for alternative agents that would be useful in anxiety conditions. Old classes of antidepressants, such as tricyclic antidepressants and monoamine oxidase inhibitors, showed effectiveness in some anxiety syndromes, even in areas where benzodiazepines were not very effective. Newer antidepressants, the selective serotonin-reuptake inhibitors, also appear very useful in some anxiety states, and their favourable side-effect profile has elevated them to first-line treatment tools in these conditions. However, the ideal anxiolytic does not exist. Research with other new compounds is very active, and some experimental drugs show promise for the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11337026     DOI: 10.1016/s0163-7258(00)00083-8

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  13 in total

1.  Effects of acute or chronic administration of novel 3,4-dimethoxyphenylethylamine derivates on anxiety-like behavior.

Authors:  Julia Fedotova; Victoria Barishpolec; Anthony Zulli; Dietrich Büsselberg; Ludovit Gaspar; Peter Kruzliak
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

2.  Anxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration.

Authors:  Aaron Ettenberg; Rick E Bernardi
Journal:  Pharmacol Biochem Behav       Date:  2006-10-24       Impact factor: 3.533

3.  Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo.

Authors:  Nicole R Sullivan; James W Crane; Katerina J Damjanoska; Gonzalo A Carrasco; Deborah N D'Souza; Francisca Garcia; Louis D Van de Kar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-18       Impact factor: 3.000

4.  Involvement of dorsal raphe nucleus and dorsal periaqueductal gray 5-HT receptors in the modulation of mouse defensive behaviors.

Authors:  Roger L H Pobbe; Helio Zangrossi; D Caroline Blanchard; Robert J Blanchard
Journal:  Eur Neuropsychopharmacol       Date:  2010-05-31       Impact factor: 4.600

5.  γ-aminobutyric acid transporter-1 is involved in anxiety-like behaviors and cognitive function in knockout mice.

Authors:  Xue Gong; Yiye Shao; Bing Li; Long Chen; Cuicui Wang; Yinghui Chen
Journal:  Exp Ther Med       Date:  2015-06-15       Impact factor: 2.447

6.  Mapping convulsants' binding to the GABA-A receptor chloride ionophore: a proposed model for channel binding sites.

Authors:  A V Kalueff
Journal:  Neurochem Int       Date:  2006-09-07       Impact factor: 3.921

Review 7.  The signal attenuation rat model of obsessive-compulsive disorder: a review.

Authors:  Daphna Joel
Journal:  Psychopharmacology (Berl)       Date:  2006-07       Impact factor: 4.530

Review 8.  Defensive and Emotional Behavior Modulation by Serotonin in the Periaqueductal Gray.

Authors:  Priscila Vázquez-León; Abraham Miranda-Páez; Kenji Valencia-Flores; Hugo Sánchez-Castillo
Journal:  Cell Mol Neurobiol       Date:  2022-07-28       Impact factor: 4.231

9.  Effects of buspirone on the immediate positive and delayed negative properties of intravenous cocaine as measured in the conditioned place preference test.

Authors:  Aaron Ettenberg; Rick E Bernardi
Journal:  Pharmacol Biochem Behav       Date:  2007-05-04       Impact factor: 3.533

Review 10.  Neurobiology of memory and anxiety: from genes to behavior.

Authors:  Allan V Kalueff
Journal:  Neural Plast       Date:  2007-01-10       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.